In this study, we evaluate the relationship between EMP2 and bevacizumab in a series of clinical glioblastoma specimens, and we identify increased EMP2 expression in tumor samples after bevacizumab treatment, proportional to the length of bevacizumab treatment. Here, EMP2 is linked to neoplasm.